IPA, a biotherapeutic, innovation-powered company, completed the acquisition of a 25% stake in BioStrand, a technology company in the field of bioinformatics and biotechnology, for $20bn. This transaction is expected to create short and long-term commercialization opportunities with clients and partners by introducing a novel AI-powered protein-protein interactions prediction platform and fortifying IPA’s sequencing with massive throughput capabilities in omics interrogation. The Company anticipates that the transaction will not only attract new clients and partners but will also enable its subsidiary, Talem Therapeutics, to access unparalleled AI technologies to help power each stage of its therapeutic antibody development.